Grant Award Details

Phase 1 Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Adults with Recurrent or Refractory B Cell Malignancies
Grant Number: 
CLIN2-10846
Project Objective: 
  • To complete a Phase 1 Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Adults with Recurrent or Refractory B Cell Malignancies.

Investigator: 
Institution: 
Type: 
PI
Disease Focus: 
B cell cancers
Blood Cancer
Cancer
Leukemia
Human Stem Cell Use: 
Adult Stem Cell
Cell Line Generation: 
Adult Stem Cell
Award Value: 
$11,034,982
Status: 
Pre-Active

Grant Application Details

Application Title: 
  • Phase 1 Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Adults with Recurrent or Refractory B Cell Malignancies
Public Abstract: 

Therapeutic Candidate or Device

T cells genetically engineered to express as bispecific Chimeric Antigen Receptor (CAR) targeting CD19 and/or CD22

Indication

Patients with relapsed and refractory B cell malignancies

Therapeutic Mechanism

T cells expressing the bispecific CAR will recognize cancer cells expressing one of both of the target antigens. Upon recognition, the T cells will become activated, divide, and then kill the cancer cells. Progenitor T cells contained within the larger population will form memory stem cells that will persist and continue to survey the body and kill residual cancer. These cancer killing T cells are designed to persist for years following one treatment with CD19/22-CAR T cells.

Unmet Medical Need

50% or less of patients with diffuse large B cell lymphoma and B cell leukemia are cured with standard regimens, that rely on chemotherapy for benefit. CD19/22-CAR T cells effectively kill chemotherapy resistant lymphoma and leukemia and thus could improve cure rates for these aggressive cancers.

Project Objective

Phase 1 trial completed

Major Proposed Activities

  • Demonstrate feasibility of producing CD19/22-CAR T cells
  • Assess toxicity of CD19/22-CAR T cells
  • Assess clinical activity of CD19/22-CAR T cells in adults with B-ALL and DLBCL.
Statement of Benefit to California: 

In California, approximately 2000 adults are diagnosed annually with DLBCL and 600 with B-ALL.. At least one third will not respond to chemotherapy based treatment and most will die of their disease within one year. The CD19/22-CAR provides a new, potentially effective therapy for these patients.. It could demonstrate both a higher response rate and greater long-term effectiveness than the CD19-CAR that has recently received FDA approval for these patients.